Impower010 clinicaltrials.gov

Author: esmn

August undefined, 2024

Witryna19 lut 2015 · ClinicalTrials.gov Identifier: NCT02366143 Other Study ID Numbers: GO29436 2014-003207-30 ( EudraCT Number ) First Posted: February 19, 2015 Key Record Dates: Results First Posted: October 27, 2024: Last Update Posted: September 23, 2024 Last Verified: August 2024 WitrynaIntroduction: IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and ALK-negative (wild type [WT]) metastatic NSCLC with high programmed death-ligand 1 (PD-L1) expression (≥50% on tumor cells [TCs] or ≥10% on tumor-infiltrating immune cells …

PL03.09 IMpower010:Overall Survival Interim Analysis of a Phase …

WitrynaIMpower010研究既往公布的数据主要是无病生存期（DFS）的结果，研究显示阿替利珠单抗辅助治疗，用于PD-L1肿瘤细胞（TC）表达≥1%，且经手术切除和以铂类为基础辅助化疗后的II-IIIA期患者，具有显著的DFS获益，患者疾病复发或死亡风险降低34%（DFS HR=0.66,P=0.004），治疗组患者的3年DFS率达到60% [1] 。基于以上数据，阿替 … Witryna21 maj 2024 · Overall survival data are awaited from IMpower010 and PEARLS. There are two additional pivotal phase III trials evaluating durvalumab (ClinicalTrials.gov identifier: NCT02273375) and nivolumab (NCT02595944) . Additionally, biomarkers to select patients most likely to benefit from checkpoint inhibitors in the early-stage … mayflower 400th anniversary

Adjuvant atezolizumab after adjuvant chemotherapy in ... - Europe …

Witryna1 wrz 2024 · IMpower010 (NCT02486718) was the first Phase III immunotherapy study to show a statistically significant disease-free survival (DFS) benefit with adjuvant atezolizumab vs best supportive care (BSC) in resected NSCLC following platinum-based chemotherapy (Felip et al. Lancet 2024). ... This trial is registered with … Witryna13 sie 2024 · The IMpower010 study has found that immune adjuvant therapy after postoperative chemotherapy can significantly prolong disease-free survival. A number … Witryna28 maj 2024 · 8500 Background: Adjuvant platinum-based chemotherapy (chemo) provides only a modest 5-year survival benefit in fully resected, high-risk early-stage NSCLC. We report the primary disease-free survival (DFS) results from the pre-planned interim analysis of IMpower010, a randomized phase 3 open-label trial of adjuvant … mayflower 400 harwich half marathon

Updated Overall Survival Analysis From IMpower110 ... - PubMed

Impower010 clinicaltrials.gov

Adjuvant atezolizumab after adjuvant chemotherapy in resected …

WitrynaIMpower010 (ClinicalTrials.gov identifi er NCT02486718), a randomized, global, open-label trial of atezolizumab (Tecentriq), an anti–PD-L1, versus best supportive care after adjuvant treatment, studied patients with resected stage IB to IIIA NSCLC. A total of 1280 patients were enrolled; they received 4 cycles of Witryna1 gru 2024 · Request PDF On Dec 1, 2024, C. Zhou and others published 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after ...

Did you know?

Witryna31 paź 2024 · ClinicalTrials.gov. 20. Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer [IMpower010]. ClinicalTrials.gov Identifier: NCT02486718. 21. Witryna20 wrz 2024 · IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected …

Witryna29 paź 2024 · IMpower010 (ClinicalTrials.gov identifier NCT02486718), a randomized, global, open-label trial of atezolizumab (Tecentriq), an anti–PD-L1, versus best … Witryna1 wrz 2024 · Methods IMpower010 was a randomised, multicentre, open-label, phase 3 study done at 227 sites in 22 countries and regions. Eligible patients were 18 years or older with completely resected stage...

Witryna20 lut 2015 · This randomized Phase III, multicenter, open-label study designed to evaluate the safety and efficacy of atezolizumab (an engineered anti-programmed … WitrynaResults: Three recent randomized Phase III trials reported significant improvements in disease-free survival with adjuvant immune checkpoint inhibitors or targeted therapy …

Witryna24 wrz 2024 · IMpower010 showed a disease-free survival benefit with atezolizumab versus best supportive care after adjuvant chemotherapy in patients with resected stage II–IIIA NSCLC, with pronounced benefit in the subgroup whose tumours expressed PD-L1 on 1 per cent or more of tumour cells, and no new safety signals.

Witryna20 wrz 2024 · IMpower010 is a randomised, multicentre, open-label, phase 3 study of atezolizumab versus best supportive care after adjuvant cisplatin-based chemotherapy in patients with completely resected stage IB–IIIA NSCLC, done at 227 sites in 22 countries and regions. The study was done in two phases: enrolment and randomisation. mayflower 400 lectureWitryna9 paź 2024 · IMpower010 was a randomised, multicentre, open-label, phase 3 study done at 227 sites in 22 countries and regions. Eligible patients were 18 years or older … mayflower 3 shipsWitrynaThe global, randomized, open-label IMpower010 study ( ClinicalTrials.gov: NCT02486718) is investigating the efficacy and safety of adjuvant atezolizumab versus BSC in patients with stage IB–IIIA NSCLC who received platinum-based chemotherapy after resection. 16 Atezolizumab ( n = 507) demonstrated a statistically significant … hertfordshire community nhs trust long covidWitryna6 kwi 2015 · Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), … hertfordshire community nhs trust intranetWitrynaIntroduction: IMpower110 previously revealed significant overall survival (OS) benefit with atezolizumab versus chemotherapy in patients with treatment-naive EGFR- and … hertfordshire constabulary chief constableWitrynaIMpower110 is a global, randomized, open-label, phase 3 trial designed to evaluate the efficacy and safety of atezolizumab as compared with platinum-based chemotherapy in PD-L1–selected patients... mayflower 400th anniversary medalWitrynaThe IMpower010 study showed that postoperative atezolizumab can be an option in patients without targetable mutations for reducing the possibility of postoperative relapse. Postoperative radiotherapy can be beneficial for patients with lymph node metastases (N2). ... ASCO guideline rapid recommendation update J Clin Oncol 2024 40 1127 … hertfordshire constabulary echo